Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
300.7 USD | -1.32% | -2.17% | +4.40% |
06-10 | Transcript : Amgen Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM | |
06-07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 37.91 and 24.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.40% | 161B | C+ | ||
+48.53% | 780B | C+ | ||
+41.23% | 627B | B | ||
-6.37% | 353B | C+ | ||
+20.93% | 334B | B- | ||
+8.21% | 296B | C+ | ||
+17.58% | 244B | B+ | ||
-0.98% | 217B | A+ | ||
+11.31% | 214B | B- | ||
-2.64% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMGN Stock
- Ratings Amgen Inc.